At the news
? BEARISHIMPACT 6/10 8-K filed Apr 6, 2026 at 07:03 ET
Inovio Pharmaceuticals entered into a material definitive agreement (Item 1.01) to conduct a public offering of 12.5 million shares of common stock and accompanying warrants, raising approximately $16.45 million in gross proceeds before expenses. This offering, combined with a recent capital raise, indicates the company is securing funds amid ongoing uncertainty about its ability to continue as a going concern, leading to significant shareholder dilution.
- Inovio Pharmaceuticals is conducting a public offering of 12,500,000 shares of common stock, Series A warrants to purchase up to 12,500,000 shares, and Series B warrants to purchase up to 12,500,000 shares.
- The combined public offering price is $1.40 per share and accompanying warrants, with gross proceeds of $17.5 million and net proceeds of approximately $16.45 million after underwriting discounts.
- The offering includes an over-allotment option for up to an additional 1,875,000 shares and warrants.
- This capital raise follows a recent 424B5 filing, indicating a pattern of dilutive financing to fund operations.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access